Stock analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Get Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.
Organovo Stock Performance
Shares of NASDAQ:ONVO opened at $1.80 on Wednesday. The business has a fifty day moving average of $1.99 and a 200-day moving average of $1.87. The firm has a market cap of $15.68 million, a PE ratio of -1.31 and a beta of 0.89. Organovo has a twelve month low of $1.37 and a twelve month high of $3.72.
Hedge Funds Weigh In On Organovo
Several large investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Organovo during the 3rd quarter valued at $30,000. Susquehanna International Group LLP raised its stake in shares of Organovo by 20.9% during the 1st quarter. Susquehanna International Group LLP now owns 61,266 shares of the medical research company’s stock valued at $134,000 after purchasing an additional 10,594 shares during the period. Renaissance Technologies LLC increased its stake in Organovo by 17.3% in the 1st quarter. Renaissance Technologies LLC now owns 131,487 shares of the medical research company’s stock worth $288,000 after acquiring an additional 19,430 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Organovo by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 283,074 shares of the medical research company’s stock worth $580,000 after acquiring an additional 13,153 shares during the last quarter. 23.07% of the stock is currently owned by institutional investors.
About Organovo
Organovo Holdings, Inc is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Get a free copy of the StockNews.com research report on Organovo (ONVO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
